LFX-PGB Opioid Outpatient Withdrawal
Brief description of study
This study will examine the safety and effectiveness of lofexidine/pregabalin compared to lofexidine/placebo for managing opioid withdrawal in an outpatient settings. The study timeline is Screening from 1-30 days; dosing for 1-7 days, and a sttudy medication taper on days 8, 9, 10; Day 8 is also 1st dose of Vivitrol; day 11 is f/U for wellness, and Day 28 is 2nd injection of Vivitrol The primary outcome will be measured by the Subjective Opioid Withdrawal Scale (SOWS) from the two arms collected in the study. The two arms are Lofexidine plus active pregabalin vs Lofexidine plus Placebo pregabalin. The secondary outcome measure is proportion that receive one or more doses of study medication and complete withdrawal (completion defined as receiving one or more doses of study medication on day 8); and proportion that transition to XR-NTX
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
